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ABSTRACT: Currently, traumatic brain injury (TBI) is detected by medical imaging; however, medical imaging requires ex-
pensive capital equipment, is time- and resource-intensive, and is poor at predicting patient prognosis. To date, direct meas-
urement of elevated protease activity has yet to be utilized in order to detect TBI. In this work, we engineered an activity-
based nanosensor for TBI (TBI-ABN) that responds to increased protease activity initiated after brain injury. We establish 
that a calcium-sensitive protease, calpain-1, is active in the injured brain hours within injury. We then optimize the molecular 
weight of a nanoscale polymeric carrier to infiltrate into injured brain tissue with minimal renal filtration. A calpain-1 sub-
strate that generates fluorescent signal upon cleavage was attached to this nanoscale polymeric carrier to generate an engi-
neered TBI-ABN. When applied intravenously to a mouse model of TBI, our engineered sensor is observed to locally activate 
in the injured brain tissue. This TBI-ABN is the first demonstration of a sensor that responds to protease activity to detect 
TBI. 
Traumatic brain injury (TBI) affects over 2.8 mil-
lion people annually in the United States and leads 
to the hospitalization of ~300,000 patients per 
year.1 Among TBI patients who require surgical in-
tervention, there is a 50% lower mortality rate and 
decreased length of stay if they receive surgery 
within 4 hours of hospital admission,2 indicating 
the importance of rapid diagnosis and triage to im-
prove outcomes. However, current diagnosis is 
achieved by medical imaging, typically computed 
tomography (CT) and magnetic resonance imaging 
(MRI), both of which are time- and resource-inten-
sive and have a limited ability to predict patient 
prognosis.3 Moreover, while medical imaging can 
identify macroscopic structural deformations in the 
brain, it currently does not yield information on the 
destructive biological activity that may unfold after 
injury. This secondary injury, which may include 
sustained protease activity, inflammation, exci-
totoxicity, and neuronal death, begins immediately 
after the primary injury and may lead to chronic 
neurodegeneration and a poorer patient progno-
sis.4 Thus, a diagnostic that yields information on 
biological activity may inform improved clinical 
care.  
Breakdown products shed into the blood and cer-
ebrospinal fluid have been recently investigated as 
biomarkers to detect pathological processes in TBI.5 
These breakdown products originate from the deg-
radation of nervous tissue as part of a prolonged 
secondary injury that begins within minutes after 
TBI.6 To date there is only one TBI biomarker-based 
diagnostic on the market; it is based on two sepa-
rate ELISAs to measure serum levels of the break-
down products GFAP and UCH-L1.7 However, meas-
urement of these biomarkers relies on the genera-
tion, stability, and transport of these byproducts;8 
direct measurement of degradative activity may be 
more representative of disease and therefore pro-
vide information that is more actionable for inter-
vention. Calpain-1, a calcium-dependent protease 
expressed in neurons, glia, and endothelial cells 
within the brain, undergoes sustained activation af-
ter TBI due to pathological elevations of intracellu-
lar calcium.6,9,10 Calpain-1 activity generates many 
breakdown products that are currently under inves-
tigation as biomarkers for TBI, including myelin 
basic protein, neurofilaments, and αII-spectrin.5 
Calpain-1 inhibition has been under investigation 
as a treatment for TBI,11 and its byproducts can po-
tentially predict patient prognosis after mild and se-
vere TBI,12,13 highlighting the importance of cal-
pain-1 in the injury sequelae and its prognostic po-
tential. Thus, the detection of calpain-1 protease ac-
tivity is a promising candidate for TBI diagnosis. 
To explore the potential of activity-based sensors 
to detect TBI, our goal was to engineer a vascularly-
 administered sensor that can accumulate in injured 
brain tissue and produce a signal in response to cal-
pain-1 activity (Figure 1A). A similar activity-based 
sensor strategy has been demonstrated for the sen-
sitive detection of cancer and liver fibrosis in previ-
ous work (REF), but has yet to be applied to any 
brain disorders. First, we established increased cal-
pain-1 activity that is independent of calpain-1 ex-
pression levels in the first few hours after TBI in 
mice, validating the need for a sensor of enzyme ac-
tivity rather than enzyme levels. In order to engi-
neer a diagnostic that can be delivered into the vas-
culature, we exploit size-dependent accumulation 
of nanoscale polymeric carriers into the site of in-
jury, where the blood brain barrier (BBB) is com-
promised and allows extravasation of nanoscale 
materials. To detect calpain-1 activity, we engi-
neered a FRET peptide which activates in the pres-
ence of active calpain-1. Combining the peptide and 
carrier, we engineered a TBI activity-based na-
nosensor, TBI-ABN. This TBI-ABN activates at the 
site of injury in a mouse model of brain injury after 
intravenous administration. To our knowledge, TBI-
ABN is the first demonstration of an activity-based 
sensor for TBI. 
 
Experimental Section 
Synthesis of PEG Conjugates. Calpain substrate 
peptide (QSY21-QEVYGAMP-K(Cy5)-PEG2-GC-
NH2) was synthesized by CPC Scientific Inc. 
(Sunnyvale, CA, USA). PEG2 is polyethylene glycol. 
8-arm PEG amine and PEG maleimide (tripentae-
rythritol) were purchased from Jenkem Technology 
(Beijing, China). PEG amine was reacted with 1 mole 
equivalent of VivoTag-S 750 (PerkinElmer, Boston, 
MA, USA). PEG maleimide was reacted with 1, 2, and 
4 mole equivalences of peptide in the presence of 50 
mM triethylamine (TEA) and quenched with an ex-
cess of cysteine. All conjugates were dialyzed into 
water, and final concentrations were determined by 
absorbance of VivoTag or Cy5 using a Spark Multi-
mode Microplate Reader (Tecan Trading AG, Swit-
zerland). The L-cysteine PEG maleimide control 
was dissolved by weight. Hydrodynamic diameters 
of unconjugated PEG amine were measured via DLS 
with a Zetasizer Nano (Malvern Panalytical). 
In vitro reaction kinetics assay. Free peptide 
and conjugates were incubated with 26.6 nM re-
combinant human calpain-1 (Sigma-Aldrich) in 50 
mM HEPES, 50 mM NaCl, 2 mM EDTA, 5 mM CaCl2, 
5 mM beta-mercaptoethanol, 10% mouse plasma in 
PBS, or 13.5 nM human alpha-thrombin (Haemato-
logic Technologies) in TCNB buffer. Mouse plasma 
was prepared by centrifuging blood collected with 
EDTA. Fluorescence readings were taken every 90 
seconds at 37 °C for 1 hour. Reaction curves were 
normalized to controls, and their initial velocities 
were fitted to a Michaelis-Menten curve in 
GraphPad Prism (8.1.2). 
Controlled cortical impact (CCI) mouse model 
of TBI. All mouse protocols were approved by the 
University of California San Diego’s Institutional 
Animal Care and Use Committee (IACUC). 8-12 
week old female C57BL/6J mice (Jackson Labs) 
were used for all experiments. Mice were anesthe-
tized with 2.5% isoflurane and the head was se-
cured in a stereotaxic frame. A midline incision was 
made to expose the skull, and a 4 mm diameter cra-
niotomy was performed over the right hemisphere 
between bregma and lambda. The controlled corti-
cal impact was applied to the exposed dura of the 
cortex with the ImpactOne (Leica Biosystems) fitted 
with a stainless steel 2 mm diameter probe at a ve-
locity of 3 m/s and a 2 mm depth. 
Biodistribution and in vivo sensor activation. 
2 hours after CCI, 2 nmoles of VivoTag-PEG in 100 
µL PBS (n=4 each for biodistribution) or 8 nmoles 
of TBI-ABN in 100 µL PBS (n=6 for sensor activation 
analysis) were intravenously administered via the 
tail-vein. Control mice received the same volume of 
PBS. 2 hours after administration, mice were trans-
cardially perfused with USP saline followed by 10% 
formalin. Fluorescence was measured with an Od-
yssey scanner (Li-Cor Biosciences) on the same day 
as collection. Mean fluorescence intensity per area 
was analyzed using ImageJ. 
Immunohistochemistry and sensor quantifi-
cation in brain tissue slices. Organs were fixed 
with 10% formalin solution at 4 °C overnight, equil-
ibrated in 30% w/v sucrose, and frozen in OCT (Tis-
sue-Tek). 10 µm thick coronal tissue slices were 
stained using conventional protocols. The following 
primary antibodies were used: 1:200 calpain-1 
(Abcam, ab108400), and 1:200 CD31 (BD, 553370). 
Sensor activation was quantified in 3 tissue slices 
per brain up to 1.5 mm caudal from the center of in-
jury. Cy5 signal in each slice extending 1.5 mm down 
from the top of the cortex was averaged between 
slices from each brain then normalized to the signal 
from uninjured PBS controls using ImageJ. Images 
were captured with a Nikon Eclipse Ti2 microscope 
fitted with a Hamamatsu Orca-Flash 4.0 digital cam-
era.  
Protein analysis. At the designated time points 
after injury, injured and contralateral cortices were 
harvested and immediately frozen. Sham injured 
 mice received a craniotomy and no injury and tissue 
was harvested 3 hours after surgery. Western blots 
were performed following conventional protocols. 
The following primary antibodies were used:  
 
Figure 1. Design of a TBI activity-based nanosensor. (A) Overview of TBI-ABN design. (B) Time course post-injury (PI) of αII-spectrin 
cleavage in CCI-injured cortices. (C) Quantification of calpain-1-specific 145 and 150 kDa αII-spectrin breakdown products (SBDP), 
normalized to α-tubulin and untreated control (n=3, mean ± SE, *p<0.05, ***p<0.001, two-way ANOVA and Dunnett’s post-hoc test 
against uninjured control). (D) Time course and (E) quantification of 80 kDa calpain-1 denoted by the arrow normalized to α-tubulin 
and untreated control (n=3, mean ± SE). Uninjured (U) mice received no surgery. Sham (S) mice received a craniotomy and no injury. 
1:2000 αII-spectrin (Abcam, ab11755), 1:1000 cal-
pain-1 (Abcam, ab108400), or 1:5000 α-tubulin 
(Cell Signaling, 3873). Membranes were imaged on 
a Li-Cor Odyssey scanner and densitometric analy-
sis of the western blots was done in ImageJ. 
Software and Statistics. All data was analyzed in 
GraphPad Prism (8.1.2). All post-hoc tests were 
conducted with p<0.05 to identify statistical signif-
icance between samples. All images were analyzed 
with ImageJ (1.52p).  
Results and Discussion 
Calpain-1 locally activates in a mouse model of 
TBI. We first established the levels of calpain-1 ac-
tivity and protein levels in a mouse model of TBI. 
The controlled cortical impact (CCI) model of TBI is 
a reproducible and well-characterized method to 
create a localized injury in the brain.14–16 To assess 
calpain-1 activity,  150 kDa and 145 kDa breakdown 
products of the native calpain-1 substrate αII-spec-
trin were measured, as described previously.17 
These spectrin breakdown products (SBDP) were 
shown to increase to greater than 10-fold in the in-
jured hemisphere at 3 hours post injury compared 
to uninjured brains (Figure 1B, C). This increase 
was sustained up to 96 hours post injury. By con-
trast, the uninjured, contralateral hemisphere did 
not show significant elevation of SBDPs. A sham 
control group that underwent a craniotomy but no 
injury exhibited similar levels of SBDPs to uninjured 
mice, confirming that spectrin proteolysis was the 
result of direct impact to the brain tissue and not 
the surgical procedures. We thus establish that cal-
pain-1 activity is increased after CCI and activity is 
localized to the injured hemisphere, consistent with 
previously reported rodent models of CCI.15,17–19 
To determine that increased spectrin cleavage 
was due to increased activity of calpain-1 and not 
 increased levels of calpain-1, calpain-1 protein lev-
els were also measured. No significant changes 
were observed in the protein levels of the 80 kDa 
large subunit of calpain-1 between injured and un-
injured brains (Figure 1D, E). Furthermore, assess-
ment of calpain-1 via immunohistochemistry of 
 
Figure 2.  Large molecular weight PEG carriers localize to the region of injury in a mouse model of TBI. (A) Fluorescence image of 
major organs after intravenous injection of fluorescently-labeled PEG of various sizes (left) were quantified and signal normalized 
to PBS injected animals (right) (n=4, mean ± SE, *p<0.05, **p<0.01, ****p<0.001, ordinary one-way ANOVA and Tukey’s post-hoc test 
compared within each organ). (B) PEG distribution in injured or contralateral brain hemispheres (n=4, mean ± SE, ***p<0.001, 
****p<0.0001, two-way ANOVA and Sidak’s post-hoc test within each size). (C) Size distribution of 10 kDa, 20 kDa, and 40 kDa PEG.
brain slices showed only a local increase in calpain-
1 detected 4 hours post-injury in the immediate in-
jury area, whereas calpain-1 levels appeared to be 
unchanged in the uninjured cortex and the greater 
injury periphery when compared to uninjured 
brains (Figure S1). These results indicate that the 
observed increase in αII-spectrin proteolysis (Fig-
ure 1B) is likely due to increased calpain-1 activity 
and not increased calpain-1 expression. Previous 
studies have shown that calpain-1 expression can 
be increased after injury, but its elevation is delayed 
by ~24 hours.20 Therefore a sensor to detect cal-
pain-1 activity may be effective in the first few 
hours after TBI. 
Large molecular weight polymeric carriers ac-
cumulate in the site of injury after CCI. We next 
focused on a nanoscale delivery carrier for our na-
nosensor. Shortly after TBI, the vasculature at the 
site of injury is compromised due to the mechanical 
damage followed by dysregulation of the neurovas-
cular unit.21,22 This pathological hallmark of TBI al-
lows for the delivery of nanoscale cargo to the brain 
within the first 24 hours after injury, similar to the 
enhanced permeability and retention (EPR) effect 
described for nanoparticles in tumors.23 On their 
own, small peptides have a short circulation half-
life in vivo due to renal clearance and proteolytic 
degradation in the bloodstream. We hypothesized 
that blood circulation time and subsequent tissue 
retention of the peptide would increase through its 
conjugation to a larger, neutrally-charged, and min-
 imally immunogenic polymeric carrier such as pol-
yethylene glycol (PEG).24 While studies have been 
done on the biodistribution of rigid nanoparticles, 
including PEGylated polystyrene nanoparticles and 
liposomes after TBI,25,26 and polystyrene nanoparti-
cles after microdialysis probe insertion,27 there has 
not yet been a study into the distribution of PEG af-
ter TBI. 
 
Figure 3. Calpain substrate is cleaved by calpain-1 as free peptide and when conjugated to PEG carrier. (A) Schematic of calpain 
substrate peptide, conjugated to 8-arm PEG to form TBI-ABN (Q=quencher, F=fluorophore). (B) Cleavage of free peptide (left) and 
1:1 peptide:PEG (right) with recombinant human calpain-1 (n=3, mean ± SD). (C) Cleavage of 8 µM peptide with recombinant human 
calpain-1, mouse plasma, or human alpha-thrombin (n=3, mean ± SD). (D) Michaelis-Menten reaction kinetics of peptide:PEG ratios 
of 1:0, 1:1, 2:1, and 4:1 calpain-1 cleavage (n=3, mean ± SD). 
To maximize the delivery of the TBI nanosensor 
through the compromised BBB after injury, we eval-
uated how the molecular weight of 8-arm PEG af-
fects its accumulation into the injured tissue after 
CCI injury. 8-arm PEG was chosen as the carrier be-
cause it allows for the possibility of multiplexing 
through conjugation of ligands to each individual 
arm. 10 kDa, 20 kDa, and 40 kDa PEG carriers were 
evaluated for distribution into major organs after 
intravenous injection 2 hours after CCI in mice 
(Figure 2A, S2). This timeline was chosen to be 
within the initial 4 hours of secondary injury after 
CCI when a quick diagnosis and intervention of cal-
pain is critical.15 The highest accumulation for 10 
kDa PEG was seen in the kidneys with little accumu-
lation in the brain, whereas the 20 kDa and 40 kDa 
PEG had significant accumulation in the injured 
brain and significantly less accumulation in the kid-
neys compared to the 10kDa PEG. In the brain, 
20kDa and 40kDa PEG accumulated significantly 
more in the injured hemisphere than in the contra-
lateral hemisphere by approximately 7-fold and 5-
fold respectively (Figure 2B). The hydrodynamic ra-
dius of each carrier in PBS was measured to be 5.57 
nm, 7.89 nm, and 10.25 nm for 10 kDa, 20 kDa, and 
40 kDa PEG, respectively (Figure 2C). 10 kDa PEG 
is near the ~5 nm limit for renal filtration,28,29 
which is reflected in its significant accumulation 
into the kidneys compared to the 20 and 40 kDa 
sizes. All three carriers are smaller than the 500 nm 
size range of materials which have been observed to 
extravasate into injured tissue following TBI.26,30 
Thus, 8-arm PEG polymer carriers greater than 
20kDa in size can accumulate in the injured brain. 
Calpain substrate responds to calpain-1 activ-
ity. To detect calpain-1 activity, we synthesized a 
calpain-1-responsive peptide comprised of the 
FRET pair Cy5 and QSY21 separated by a calpain-1-
specific cleavage sequence (QEVYGAMP) taken 
from the native mouse αII-spectrin sequence (Fig-
ure 3A).31  To measure kinetics of cleavage by cal-
pain-1, several concentrations of peptide were incu-
bated with recombinant calpain-1 enzyme in vitro 
and peptide cleavage was measured by dequenched 
Cy5 fluorescence (Figure 3B). Because blood cleav-
age is a major concern for a sensor administered in-
travenously, non-specific cleavage of our peptide by 
blood components was examined by incubation 
with mouse plasma or human alpha-thrombin. No 
significant cleavage of our substrate was observed 
 (Figure 3C). This peptide was then conjugated to 40 
kDa 8-arm PEG in order to increase its circulation 
time and retention in injured brain tissue when ap-
plied in vivo (Figure 2). 40 kDa PEG was used over 
20 kDa PEG in order to increase solubility of the 
peptide, as precipitates were observed with 20 kDa 
conjugates. Multiple ratios of peptide:PEG were as-
sessed via the same in vitro kinetics assay to opti-
 
Figure 4. Calpain sensor activates in injured brain tissue after intravenous delivery. (A-C) Representative coronal brain slices from 
injured and uninjured brains. (blue, nuclei; red, activated nanosensor; scale bar = 500 µm). (D) Quantification of mean sensor inten-
sity in the injured hemisphere normalized to uninjured control brains (n=6, mean ± SE, *p=0.0851, ordinary one-way ANOVA and 
Sidak’s post-hoc test). (E) Map and (F) insets from slices adjacent to Fig. 4A showing sensor localization relative to (i) calpain-1 and 
(ii) CD31 in the injury periphery (blue, nuclei; red, activated nanosensor; green, calpain-1 (top) or CD31 (bottom); outlined arrows, 
overlap of sensor with CD31; scale bar = 100 µm).
mize for sensor signal in response to calpain-1. It 
was observed that the conjugation of peptide:PEG 
in a 1:1 stoichiometric ratio led to a decrease in flu-
orescent signal (Figure 3B) as well as maximum 
cleavage velocity (Figure 3D) compared to free pep-
tide. For example, the maximum cleavage velocity of 
peptide at an 8 µM concentration decreased from 
1677.5 RFU/min to 692.1 RFU/min with conjuga-
tion. This decrease was not observed with peptide 
in the presence of free unconjugated PEG (Figure 
S3), suggesting that the direct conjugation of the 
peptide to PEG impacts peptide cleavage by calpain-
1. The addition of multiple peptides:PEG in 2:1 and 
4:1 conjugates led to further decreased cleavage ve-
locities compared to 1:1 conjugate or free peptide 
(Figure 3D). Conjugates of 8:1 peptide:PEG precipi-
tated out of solution, suggesting that the increased 
local concentration of peptides created by physical 
linkage to a polymeric carrier leads to a decrease in 
solubility. Due to the benefits of brain accumulation 
afforded by the PEG, a 1:1 stoichiometric ratio of 
peptide and PEG carrier was further evaluated in 
animal models of TBI. 
TBI-ABN activates in injured brain tissue after 
CCI. Finally, we tested the activation of the TBI na-
 nosensor in a mouse model of TBI. We have estab-
lished that calpain-1 has increased activity inde-
pendent of expression after brain injury, greater 
than 20 kDa molecular weight PEG can accumulate 
in the injury site, and a FRET peptide substrate is 
cleaved by calpain-1. Extracellular release of cal-
pain-1 and its substrates by necrotic neurons after 
injury has been observed in previous studies;5,32 we 
therefore expect activation of our nanosensor with-
out the need for cell internalization. Increased cal-
pain-1 activity and intravenous access to the brain 
both occur within the same 4-hour time scale post-
injury, so we expect that our TBI-ABN can localize 
and activate in the injured brain. We note that diag-
nosis of TBI within this 4-hour window has been 
demonstrated to be crucial to decrease patient mor-
bidity.2  
Mice were intravenously injected with sensor 2 
hours after CCI injury and evaluated for sensor acti-
vation 2 hours after injection. In the first hours after 
CCI, focal neurodegeneration has been previously 
been shown to extend from the injury site down to 
the hippocampus;15 based on these observations, 
the top 1.5 mm of coronal brain slices were ana-
lyzed for sensor activation after fluorescent imag-
ing. The sensor showed significant activation in the 
injured brain hemisphere with a higher activated 
sensor signal compared to background signal from 
both injured and uninjured brains (Figure 4A-C). 
There was minimal activation of the sensor in unin-
jured brains, likely due to unchanged calpain-1 ac-
tivity (Figure 1B) and intact BBB. Additionally, there 
was little difference in signal in uninjured brains 
and the contralateral hemisphere of injured brains 
(Figure 4D, S4). These results provide evidence that 
the sensor produces a signal in response to injury. 
We additionally investigated cellular distribution 
of sensor activation. Since the TBI-ABN was deliv-
ered through an intravenous injection, we assessed 
TBI-ABN activation in relation to the vasculature by 
staining for calpain-1 and the endothelial marker, 
CD31. In the injury periphery, activated TBI-ABN 
signal was found in proximity to calpain-1 and some 
signal was also positively stained for endothelial 
cells (Figure 4E,F). Signal was also detected in the 
hippocampal CA1 region and dentate gyrus (Figure 
S5), regions which are identified as sites of extrava-
sation and neurodegeneration following CCI.16,22 
Neurons, glia, and endothelial cells populating 
these regions are known to experience calcium in-
fluxes and abnormal calpain activation following in-
jury,6,9 and are therefore potential sources for TBI-
ABN signal.  
 
Conclusions 
We engineered a TBI activity-based nanosensor, 
TBI-ABN, which responds to calpain-1 activity, ac-
cumulates in injured brain tissue, and activates in a 
mouse model of brain injury. To our knowledge, our 
engineered TBI-ABN is the first sensor to detect en-
zyme activity in TBI and is a proof-of-concept for 
the development of future activity-based diagnos-
tics for TBI. Activity-based sensors are gaining sig-
nificance for their ability to be engineered in re-
sponse to specific biological stimuli, allowing for 
the capture of pathological processes that cannot be 
detected by conventional molecular quantification 
methods.33 There are notable examples of activity-
based sensors in cancer: fluorescently activated 
polymers can identify tumor margins during surgi-
cal resection34,35 and urinary sensors can detect and 
stratify tumors.36–38 Based on these advances in can-
cer, measuring protease activity with an activity-
based sensor to diagnose TBI is a promising strat-
egy. 
Now that we have established that a vascularly 
delivered sensor can activate in brain injury in re-
sponse to protease activity, in future work, the TBI-
ABN will be engineered to release biomarkers  for 
minimally-invasive blood-based detection. Signal 
specificity can be increased by multiplexing sub-
strates for the detection of proteases such as MMP-
9, which has local increases in activity following TBI 
and contributes to BBB breakdown.39 To further en-
hance sensitivity and increase tissue accumulation 
and retention, we can add active targeting ligands, 
for example peptides that bind extracellular matrix 
components exposed after injury.40–42 In the long-
term, TBI-ABN can be paired with inhibitors of pro-
tease activity, such as small molecule inhibitors of 
calpain-111 to create nanotheranostics that can de-
tect and treat TBI. 
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